Metformin ameliorates core deficits in a mouse model of fragile X syndrome

Ilse Gantois, Arkady Khoutorsky, Jelena Popic, Argel Aguilar-Valles, Erika Freemantle, Ruifeng Cao, Vijendra Sharma, Tine Pooters, Anmol Nagpal, Agnieszka Skalecka, Vinh T Truong, Shane Wiebe, Isabelle A Groves, Seyed Mehdi Jafarnejad, Clément Chapat, Elizabeth A McCullagh, Karine Gamache, Karim Nader, Jean-Claude Lacaille, Christos G Gkogkas, Nahum Sonenberg, Ilse Gantois, Arkady Khoutorsky, Jelena Popic, Argel Aguilar-Valles, Erika Freemantle, Ruifeng Cao, Vijendra Sharma, Tine Pooters, Anmol Nagpal, Agnieszka Skalecka, Vinh T Truong, Shane Wiebe, Isabelle A Groves, Seyed Mehdi Jafarnejad, Clément Chapat, Elizabeth A McCullagh, Karine Gamache, Karim Nader, Jean-Claude Lacaille, Christos G Gkogkas, Nahum Sonenberg

Abstract

Fragile X syndrome (FXS) is the leading monogenic cause of autism spectrum disorders (ASD). Trinucleotide repeat expansions in FMR1 abolish FMRP expression, leading to hyperactivation of ERK and mTOR signaling upstream of mRNA translation. Here we show that metformin, the most widely used drug for type 2 diabetes, rescues core phenotypes in Fmr1-/y mice and selectively normalizes ERK signaling, eIF4E phosphorylation and the expression of MMP-9. Thus, metformin is a potential FXS therapeutic.

References

    1. Neuron. 2012 Oct 18;76(2):325-37
    1. Cell Metab. 2014 Dec 2;20(6):953-66
    1. J Neurosci. 2014 Jul 23;34(30):9867-79
    1. Neurosci Lett. 2014 Sep 5;579:145-50
    1. Nature. 2015 Dec 10;528(7581):262-6
    1. Nat Med. 2013 Nov;19(11):1473-7
    1. J Neurochem. 2016 Jul;138(1):86-100
    1. Pharmacol Rep. 2010 Sep-Oct;62(5):956-65
    1. J Dev Behav Pediatr. 2013 Apr;34(3):147-55
    1. J Neurodev Disord. 2011 Sep;3(3):211-24
    1. Neuron. 2013 Jan 23;77(2):243-50
    1. PLoS One. 2014 Dec 10;9(12 ):e114573
    1. Cell. 2013 Dec 19;155(7):1451-63
    1. Nature. 2013 Jan 17;493(7432):371-7
    1. Am J Med Genet B Neuropsychiatr Genet. 2005 Jul 5;136B(1):98-102
    1. Stroke. 2010 Nov;41(11):2645-52
    1. Nat Methods. 2009 Apr;6(4):275-7
    1. PLoS One. 2013;8(2):e57289
    1. Cell Stem Cell. 2012 Jul 6;11(1):23-35
    1. Am J Med Genet A. 2013 Aug;161A(8):1897-903
    1. Nat Rev Mol Cell Biol. 2015 May;16(5):281-98
    1. Sci Transl Med. 2016 Jan 13;8(321):321ra5
    1. Cell Rep. 2014 Dec 11;9(5):1742-55
    1. Pain. 2006 Dec 15;126(1-3):24-34
    1. Neuromolecular Med. 2016 Dec;18(4):581-592
    1. Neuron. 2006 Aug 17;51(4):441-54

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir